CASI Pharmaceuticals Inc (CASI)
5.11
-0.14
(-2.67%)
USD |
NASDAQ |
Nov 22, 13:20
CASI Pharmaceuticals Enterprise Value: 79.48M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 79.48M |
| November 20, 2024 | 79.63M |
| November 19, 2024 | 80.87M |
| November 18, 2024 | 85.20M |
| November 15, 2024 | 80.72M |
| November 14, 2024 | 89.22M |
| November 13, 2024 | 84.12M |
| November 12, 2024 | 84.89M |
| November 11, 2024 | 84.74M |
| November 08, 2024 | 83.05M |
| November 07, 2024 | 85.20M |
| November 06, 2024 | 87.60M |
| November 05, 2024 | 90.46M |
| November 04, 2024 | 93.16M |
| November 01, 2024 | 91.23M |
| October 31, 2024 | 91.62M |
| October 30, 2024 | 92.93M |
| October 29, 2024 | 93.16M |
| October 28, 2024 | 89.07M |
| October 25, 2024 | 98.81M |
| October 24, 2024 | 88.45M |
| October 23, 2024 | 83.35M |
| October 22, 2024 | 84.12M |
| October 21, 2024 | 83.35M |
| October 18, 2024 | 84.58M |
| Date | Value |
|---|---|
| October 17, 2024 | 82.26M |
| October 16, 2024 | 81.80M |
| October 15, 2024 | 84.58M |
| October 14, 2024 | 88.29M |
| October 11, 2024 | 88.29M |
| October 10, 2024 | 89.22M |
| October 09, 2024 | 91.85M |
| October 08, 2024 | 86.44M |
| October 07, 2024 | 87.21M |
| October 04, 2024 | 83.81M |
| October 03, 2024 | 82.48M |
| October 02, 2024 | 83.81M |
| October 01, 2024 | 85.05M |
| September 30, 2024 | 93.55M |
| September 27, 2024 | 98.66M |
| September 26, 2024 | 95.10M |
| September 25, 2024 | 87.22M |
| September 24, 2024 | 90.93M |
| September 23, 2024 | 99.74M |
| September 20, 2024 | 105.77M |
| September 19, 2024 | 106.85M |
| September 18, 2024 | 110.26M |
| September 17, 2024 | 112.26M |
| September 16, 2024 | 112.26M |
| September 13, 2024 | 116.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-7.265M
Minimum
Mar 20 2023
406.87M
Maximum
Jan 26 2021
107.63M
Average
84.74M
Median
Nov 11 2024
Enterprise Value Benchmarks
| Sinovac Biotech Ltd | -6.942B |
| Zai Lab Ltd | 2.259B |
| China SXT Pharmaceuticals Inc | -8.303M |
| Adagene Inc | 24.91M |
| LakeShore Biopharma Co Ltd | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.395M |
| Revenue (Quarterly) | 7.793M |
| Total Expenses (Quarterly) | 15.88M |
| EPS Diluted (Quarterly) | -0.55 |
| Gross Profit Margin (Quarterly) | 51.91% |
| Profit Margin (Quarterly) | -107.7% |
| Earnings Yield | -43.84% |
| Normalized Earnings Yield | -45.98 |